tradingkey.logo

Bluejay Diagnostics Inc

BJDX
0.706USD
-0.039-5.27%
收盘 12/24, 13:00美东报价延迟15分钟
1.16M总市值
亏损市盈率 TTM

Bluejay Diagnostics Inc

0.706
-0.039-5.27%

关于 Bluejay Diagnostics Inc 公司

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.

Bluejay Diagnostics Inc简介

公司代码BJDX
公司名称Bluejay Diagnostics Inc
上市日期Nov 10, 2021
CEODey (Neil)
员工数量7
证券类型Ordinary Share
年结日Nov 10
公司地址360 Massachusetts Avenue, Suite 203
城市ACTON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编01720
电话19786310152
网址https://bluejaydx.com/
公司代码BJDX
上市日期Nov 10, 2021
CEODey (Neil)

Bluejay Diagnostics Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Donald R. Chase
Mr. Donald R. Chase
Independent Director
Independent Director
98.00
--
Ms. Svetlana Dey
Ms. Svetlana Dey
Director
Director
6.00
--
Mr. Douglas C. Wurth
Mr. Douglas C. Wurth
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Fred S. Zeidman
Mr. Fred S. Zeidman
Independent Director
Independent Director
--
--
Mr. Neil (Indranil) Dey
Mr. Neil (Indranil) Dey
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Donald R. Chase
Mr. Donald R. Chase
Independent Director
Independent Director
98.00
--
Ms. Svetlana Dey
Ms. Svetlana Dey
Director
Director
6.00
--
Mr. Douglas C. Wurth
Mr. Douglas C. Wurth
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Fred S. Zeidman
Mr. Fred S. Zeidman
Independent Director
Independent Director
--
--
Mr. Neil (Indranil) Dey
Mr. Neil (Indranil) Dey
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
President, Chief Executive Officer, Principal Executive Officer, Co-Founder, Principal Financial and Accounting Officer, Director
--
--

收入明细

FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
由于公司未披露,未能获取相关数据
地区USD
名称
营收
占比
United States
0.00
0.00%
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 11月20日 周四
更新时间: 11月20日 周四
持股股东
股东类型
持股股东
持股股东
占比
Intracoastal Capital, L.L.C.
9.65%
DRW Securities, LLC
3.29%
Sabby Management, LLC
1.63%
Armistice Capital LLC
0.38%
Tower Research Capital LLC
0.25%
其他
84.80%
持股股东
持股股东
占比
Intracoastal Capital, L.L.C.
9.65%
DRW Securities, LLC
3.29%
Sabby Management, LLC
1.63%
Armistice Capital LLC
0.38%
Tower Research Capital LLC
0.25%
其他
84.80%
股东类型
持股股东
占比
Corporation
9.67%
Investment Advisor
3.44%
Investment Advisor/Hedge Fund
1.86%
Hedge Fund
0.63%
Individual Investor
0.03%
其他
84.36%

机构持股

更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
21
107.69K
6.48%
--
2025Q3
22
107.69K
7.87%
-5.14K
2025Q2
22
108.63K
1.16%
+96.42K
2025Q1
23
12.21K
4.22%
-11.19K
2024Q4
24
12.14K
4.03%
-17.82K
2024Q3
26
29.96K
1.04%
+23.88K
2024Q2
26
6.08K
2.15%
+5.00K
2024Q1
24
1.08K
7.93%
+549.00
2023Q4
24
499.00
2.34%
+441.00
2023Q3
25
58.00
1.55%
+36.00
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
Sabby Management, LLC
96.03K
6.43%
+96.03K
--
Jun 30, 2025
Armistice Capital LLC
6.95K
0.47%
+6.95K
--
Sep 30, 2024
Tower Research Capital LLC
2.27K
0.15%
+533.00
+30.65%
Jun 30, 2025
Geode Capital Management, L.L.C.
4.20K
0.28%
--
--
Aug 31, 2025
Lana Management & Business Research International LLC
511.00
0.03%
--
--
May 02, 2025
Wurth (Douglas Clark)
414.00
0.03%
--
--
May 02, 2025
Chase (Donald R)
98.00
0.01%
--
--
May 02, 2025
查看更多

持股ETF

机构名称
占比
暂无数据

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Jun 17, 2024
Merger
8→1
Jun 17, 2024
Merger
8→1
公告日期
类型
比率
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Nov 13, 2024
Merger
50→1
Jun 17, 2024
Merger
8→1
Jun 17, 2024
Merger
8→1
Jun 17, 2024
Merger
8→1
Jun 17, 2024
Merger
8→1
Jul 21, 2023
Merger
20→1
Jul 21, 2023
Merger
20→1
查看更多

常见问题

Bluejay Diagnostics Inc的前五大股东是谁?

Bluejay Diagnostics Inc 的前五大股东如下:
Sabby Management, LLC持有股份:96.03K,占总股份比例:6.43%。
Armistice Capital LLC持有股份:6.95K,占总股份比例:0.47%。
Tower Research Capital LLC持有股份:2.27K,占总股份比例:0.15%。
Geode Capital Management, L.L.C.持有股份:4.20K,占总股份比例:0.28%。
Lana Management & Business Research International LLC持有股份:511.00,占总股份比例:0.03%。

Bluejay Diagnostics Inc的前三大股东类型是什么?

Bluejay Diagnostics Inc 的前三大股东类型分别是:
Intracoastal Capital, L.L.C.
DRW Securities, LLC
Sabby Management, LLC

有多少机构持有Bluejay Diagnostics Inc(BJDX)的股份?

截至2025Q4,共有21家机构持有Bluejay Diagnostics Inc的股份,合计持有的股份价值约为107.69K,占公司总股份的6.48%。与2025Q3相比,机构持股有所增加,增幅为-1.39%。

哪个业务部门对Bluejay Diagnostics Inc的收入贡献最大?

在FY2023,--业务部门对Bluejay Diagnostics Inc的收入贡献最大,创收--,占总收入的--%。
KeyAI